Drug intelligence / Profile preview

PURR-02

Development stage: Preclinical
Lead developer: The Cat Health Company
Modality: Small Molecules

Overview

PURR-02 is a veterinary therapeutic candidate developed by The Cat Health Company for the treatment of age-related conditions in senior cats, specifically sarcopenia (muscle wasting), chronic kidney disease (CKD), and neurodegeneration. Identified through a computational drug-discovery platform, PURR-02 is a repurposed and reformulated small molecule designed to modulate biological pathways associated with longevity and the molecular mechanisms of aging. The development process utilizes in silico research, computational modeling, and machine learning algorithms to optimize the compound for feline health. While its sibling candidate PURR-01 has reached clinical trials, PURR-02 remains in earlier stages of the development pipeline.

Beyond the preview

Go deeper on PURR-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PURR-02.

Explore the full profile